



**Press information – Pelago Bioscience AB**

**Release date - 01/11/2017**

**PELAGO BIOSCIENCE TAKES STRIDES TOWARDS IN VITRO DIAGNOSTIC APPLICATIONS OF CETSA®**

Pelago Bioscience has been awarded a 5.0M SEK Swelife grant to use its patented CETSA® technique to identify new oncology biomarkers to aid the treatment of childhood leukaemia.

Current treatment regimens are based on medication developed for adult cancers and there is little information to guide the appropriate regime in children, resulting in issues with reduced clinical efficacy and toxicity.

Pelago's CETSA MS format can be used to profile the effect of a drug on up to 6000 proteins. This will be applied to patient blood samples and will identify 'unique fingerprints' associated with best clinical outcomes for each of 6 commonly used cancer drugs. Initially this profiling will be offered as a service but further studies will identify the key components of the finger print and reduce the number of proteins that need to be assessed. This will enable the development of a routine diagnostic assay.

CEO of Pelago Bioscience, Dr. Michael Dabrowski comments:

“Worldwide there are around 352,000 people diagnosed with a type of leukaemia each year, and it is the most common cancer in children and teens. Working in this area, and using our CETSA® technique to help identify new oncology biomarkers to support the treatment of children with leukaemia, has been hugely helped by the injection of grant funding from Swelife.”

- ENDS -

**Notes to editors:**

Issued for and on behalf of Pelago Bioscience AB by V Formation Limited. All press enquiries, contact:

Sue Carr: e: [sue@vformation.biz](mailto:sue@vformation.biz) t: +44 (0)7809 727533

**For more information**

Pelago Bioscience AB: Michael Dabrowski, CEO, Tel. +46 (0)730 715 334, [michael@pelagobio.com](mailto:michael@pelagobio.com)

**About Pelago Bioscience:**

Pelago Bioscience AB was founded in 2013 to provide and develop the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. By using CETSA data in drug discovery projects one can make better and more informed decisions at earlier stages. This reduces time and money spent on sub optimal compounds and allows faster development of more efficacious new drugs. More information here: <https://www.youtube.com/watch?v=gnZKsZFzqAg&feature=youtu.be>

**About Swelife:**

Swelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme's collaborative partners in healthcare, academia and industry. Swelife's goal is to strengthen Swedish Life Science and improve public health. By challenging obstacles and stimulating and supporting new national solutions for innovation, Swelife's work is to contribute to: 1) the development, utilisation and evaluation of innovations in healthcare, as well as to personalised and values-based medical practice 2) making Swedish Life Science attractive and internationally competitive.